Ipratropium Bromide (Atrovent HFA)
ipratropium bromide monohydrate · Short-Acting Muscarinic Antagonist (SAMA)
Indications for Ipratropium
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Maintenance treatment of bronchospasm associated with COPD (chronic bronchitis and emphysema) | Adults | Scheduled maintenance bronchodilator | FDA Approved |
| Rhinorrhea associated with allergic and nonallergic perennial rhinitis (nasal spray 0.03%) | ≥6 years | Symptomatic relief | FDA Approved |
| Rhinorrhea associated with the common cold (nasal spray 0.06%) | ≥5 years | Symptomatic relief | FDA Approved |
Ipratropium bromide is a short-acting muscarinic antagonist (SAMA) and the most widely used inhaled anticholinergic bronchodilator. In COPD, it provides consistent bronchodilation by blocking vagal cholinergic tone in airway smooth muscle. GOLD guidelines position short-acting bronchodilators (SABA or SAMA) for initial symptomatic relief, with long-acting agents (LAMA such as tiotropium) preferred for maintenance in patients with persistent symptoms.
Acute asthma exacerbation (adjunctive with SABA): Nebulized ipratropium 0.5 mg combined with albuterol every 20 minutes for 3 doses is recommended by GINA and NAEPP for moderate-to-severe acute asthma in the emergency department. The addition of ipratropium to SABA reduces hospitalization rates. Benefit is not sustained once the patient is admitted. Evidence quality: High
Acute COPD exacerbation: Nebulized ipratropium 0.5 mg with albuterol is standard practice for acute COPD exacerbations in the ED. Evidence quality: Moderate
Atrovent HFA is indicated for the maintenance treatment of bronchospasm associated with COPD and is NOT indicated for the initial treatment of acute episodes of bronchospasm where rescue therapy is required for rapid response. A SABA (albuterol) should always be available as rescue therapy (FDA PI).
Dosing of Ipratropium
Inhaled Dosing (Atrovent HFA MDI)
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| COPD maintenance — adults (MDI) | 2 puffs (34 mcg) QID | 2 puffs QID | 12 puffs/24 h | Each actuation delivers 17 mcg from mouthpiece (21 mcg from valve) Solution aerosol — does NOT require shaking before use. Prime 2 sprays before first use or after >3 days of non-use (FDA PI) |
Nebulizer Dosing
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| COPD maintenance — adults ≥12 years (nebulizer 0.02%) | 500 mcg (0.5 mg) nebulized TID–QID | 500 mcg q6–8h | 2 mg/day (4 doses) | Deliver via jet nebulizer over 5–15 min May be mixed with albuterol in the same nebulizer; do not mix with cromolyn (incompatible) |
| Acute asthma exacerbation — adults (off-label, NAEPP/GINA) | 0.5 mg nebulized q20min ×3 doses | 0.5 mg q4–6h PRN | Per clinical judgment | Always co-administer with SABA (albuterol 2.5–5 mg); do not use as monotherapy Benefit not sustained after admission; primary value is in the first 3 hours of ED management |
| Acute asthma exacerbation — pediatric (off-label, NAEPP) | 0.25–0.5 mg nebulized q20min ×3 doses | 0.25–0.5 mg q4–6h PRN | Per clinical judgment | Use 0.25 mg for children <5 years; 0.5 mg for ≥5 years; always combine with albuterol |
Ipratropium has a slower onset (15–30 minutes) than albuterol (5–15 minutes) and provides complementary bronchodilation via a different mechanism. In acute exacerbations, it should always be co-administered with a SABA — never as sole bronchodilator therapy. The fixed combination of ipratropium 0.5 mg plus albuterol 2.5 mg (Combivent/DuoNeb) is commercially available for convenience.
Allergic/nonallergic perennial rhinitis (0.03%): 2 sprays (42 mcg) per nostril BID–TID; ages ≥6 years. Common cold rhinorrhea (0.06%): 2 sprays (84 mcg) per nostril TID–QID; ages ≥5 years; use for up to 4 days. Prime with 7 sprays before first use.
Pharmacology of Ipratropium
Mechanism of Action
Ipratropium bromide is an anticholinergic (parasympatholytic) agent that inhibits vagally-mediated reflexes by antagonizing the action of acetylcholine at muscarinic receptors (M1, M2, M3) on bronchial smooth muscle. It is a nonselective muscarinic antagonist. By blocking acetylcholine-induced increases in intracellular calcium, ipratropium prevents bronchoconstriction and reduces mucus secretion from submucosal glands. Unlike beta-agonists, ipratropium does not inhibit mast cell mediator release or enhance mucociliary clearance. Its bronchodilatory effect is most pronounced in COPD, where vagal cholinergic tone is a major contributor to airflow limitation, and relatively less prominent in asthma where inflammation-mediated bronchoconstriction predominates.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Quaternary amine — poorly absorbed from lung and GI tract; Cmax 59±20 pg/mL after single 84 mcg dose (4 puffs); steady-state peak 82±39 pg/mL with QID dosing | Very low systemic bioavailability minimizes systemic anticholinergic side effects (dry mouth, urinary retention, constipation); does not cross blood-brain barrier |
| Distribution | Minimally bound to plasma proteins (0–9% in vitro to albumin and α1-acid glycoprotein) | Low protein binding means drug-displacement interactions are not clinically significant |
| Metabolism | Partially metabolized to inactive ester hydrolysis products; not a CYP substrate | No CYP-mediated drug interactions; metabolism is primarily non-enzymatic hydrolysis |
| Elimination | t½ ~2 h (inhalation and IV); ~50% excreted unchanged in urine after IV dosing; after nebulization, ~4% excreted unchanged in urine (reflecting low systemic absorption) | Short half-life supports QID dosing; renal clearance exceeds GFR, indicating active tubular secretion |
Side Effects of Ipratropium
Adverse event data for Atrovent HFA are derived from two 12-week, double-blind, placebo-controlled studies and one 1-year open-label study in 1,010 COPD patients (Atrovent HFA N=243, placebo N=128 in the 12-week study; Atrovent HFA N=305 in the 1-year study). Drug-related adverse events occurred in 9.3% of Atrovent HFA patients; the most common were dry mouth (1.6%) and taste perversion (0.9%) (FDA PI).
| Adverse Effect | 12-Week Study | Placebo | 1-Year Study | Clinical Note |
|---|---|---|---|---|
| Bronchitis | 10% | 6% | 23% | May reflect COPD-related intercurrent infections rather than drug effect; higher 1-year rate consistent with chronic disease course |
| COPD exacerbation | 8% | 13% | 23% | Placebo rate was actually higher in the 12-week study (13% vs 8%), suggesting ipratropium may reduce exacerbation risk |
| Dyspnea | 8% | 4% | 7% | Assess for paradoxical bronchospasm vs underlying disease progression |
| Headache | 6% | 8% | 7% | Comparable to placebo; likely disease or population-related |
| Adverse Effect | 12-Week Study | Placebo | 1-Year Study | Clinical Note |
|---|---|---|---|---|
| Dry mouth | 4% | 2% | 2% | Classic anticholinergic effect; most common drug-related AE (1.6% investigator-attributed); usually mild; good oral hygiene important |
| Nausea | 4% | 2% | 4% | May relate to swallowed drug fraction with bitter taste |
| Influenza-like symptoms | 4% | 2% | 8% | Likely intercurrent infection rather than drug effect |
| Dizziness | 3% | 2% | 3% | Advise caution with driving and operating machinery |
| Back pain | 2% | 2% | 7% | Comparable to placebo in short-term; higher in 1-year study |
| UTI | 2% | 1% | 10% | Consider relationship to anticholinergic urinary retention effects in elderly COPD patients |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Paradoxical bronchospasm | Rare | During or shortly after inhalation | Discontinue immediately; institute alternative bronchodilator; may be life-threatening |
| Narrow-angle glaucoma / increased IOP | Uncommon | Minutes to hours; especially if sprayed into eyes or nebulized with face mask | Eye pain, blurred vision, mydriasis, visual halos, conjunctival congestion; consult ophthalmology urgently; avoid spraying into eyes |
| Urinary retention | Uncommon (post-marketing) | Hours to days; more common in males with BPH | Caution in patients with prostatic hyperplasia or bladder-neck obstruction; may require catheterization |
| Anaphylaxis / angioedema | Rare (post-marketing) | During or shortly after administration; positive rechallenge reported | Discontinue at once; treat with epinephrine; do not rechallenge; note cross-reactivity with atropine derivatives |
| SVT / atrial fibrillation | 0.5% (5-year placebo-controlled trial, post-marketing) | Variable | ECG monitoring if symptoms develop; evaluate cardiac status |
When ipratropium is delivered via nebulizer with a face mask, inadvertent ocular exposure to the aerosol can precipitate or worsen narrow-angle glaucoma. Clinicians should use a mouthpiece rather than a face mask whenever possible. If a face mask is necessary (e.g., in young children or debilitated patients), ensure it fits snugly to minimize eye exposure, and monitor for eye pain or visual disturbance.
Drug Interactions with Ipratropium
Ipratropium has a minimal systemic drug interaction profile because it is a quaternary amine with negligible systemic absorption. Its primary interaction concern is pharmacodynamic: additive anticholinergic effects when combined with other anticholinergic agents. It is not a CYP substrate and does not alter hepatic drug metabolism.
Monitoring for Ipratropium
- Pulmonary FunctionPeriodic spirometry
RoutineAssess FEV1 response to ipratropium maintenance therapy. If bronchodilator response is inadequate, consider switching to a LAMA (tiotropium) or adding LABA therapy per GOLD guidelines. - Ocular SymptomsEach visit; urgently if symptomatic
Trigger-basedAsk about eye pain, blurred vision, visual halos, or red eyes. Particularly important in patients with narrow-angle glaucoma or when using nebulizer with face mask. Refer urgently to ophthalmology if symptoms develop. - Urinary SymptomsAt initiation and periodically
Trigger-basedAssess for urinary retention symptoms (difficulty starting stream, incomplete emptying, straining) especially in males with BPH or bladder-neck obstruction. - Anticholinergic BurdenMedication review
RoutineReview concurrent anticholinergic medications (bladder agents, antihistamines, TCAs, antipsychotics). Cumulative anticholinergic burden increases risk of cognitive impairment, falls, and constipation in elderly patients. - Treatment Response4–8 weeks after initiation
RoutineEvaluate symptom control, inhaler technique, and adherence to QID regimen. COPD patients with persistent symptoms despite SAMA therapy may benefit from stepping up to a LAMA which requires only once-daily dosing.
Contraindications & Cautions for Ipratropium
Absolute Contraindications
- Hypersensitivity to ipratropium bromide or other Atrovent HFA components — reactions include urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema (FDA PI)
- Hypersensitivity to atropine or any of its derivatives — ipratropium is a synthetic quaternary ammonium derivative of atropine (FDA PI)
Use with Caution
- Narrow-angle glaucoma: Ipratropium may increase intraocular pressure, precipitating or worsening narrow-angle glaucoma. Patients should avoid spraying into eyes. If using nebulizer, prefer mouthpiece over face mask.
- Prostatic hyperplasia / bladder-neck obstruction: Anticholinergic effects may worsen urinary retention. Instruct patients to report difficulty with urination.
- Pregnancy: Published literature (cohort studies, case-control studies, case series) has not identified a drug-associated risk of major birth defects or miscarriage. No teratogenicity in animal studies at up to 200–40,000 times MRHDID. Negligible systemic absorption makes fetal exposure unlikely (FDA PI 2025).
- Lactation: Unknown whether excreted in human milk. Quaternary cations may pass into breast milk; however, plasma levels after inhaled therapeutic doses are very low, so milk levels are expected to be minimal.
- Pediatric (MDI): Safety and efficacy not established for Atrovent HFA in the pediatric population. Nasal spray formulations are approved from age 5–6 years. Off-label nebulized use in acute asthma exacerbations is supported by NAEPP/GINA guidelines.
- Elderly: 57% of clinical trial subjects were ≥65 years. No overall differences in safety or efficacy observed compared to younger patients. Pharmacokinetics were consistent between older and younger COPD patients.
Patient Counselling for Ipratropium
Purpose of Therapy
Ipratropium (Atrovent HFA) is a maintenance bronchodilator used to keep the airways in your lungs open on a regular basis. It works differently from albuterol — it blocks nerve signals that cause the airways to tighten. It is NOT a rescue inhaler and should not be used to treat sudden breathing emergencies. You should always carry a separate rescue inhaler (such as albuterol) for acute shortness of breath.
How to Use
You do NOT need to shake the Atrovent HFA canister before use. Prime the inhaler with 2 test sprays before the first use or after more than 3 days of non-use. Place your lips firmly around the mouthpiece, press the canister while breathing in slowly and deeply, then hold your breath for up to 10 seconds. Avoid spraying the medication into your eyes. Discard the inhaler when the dose indicator shows zero (200 actuations).
Sources
- ATROVENT HFA (ipratropium bromide HFA inhalation aerosol). Full Prescribing Information. Boehringer Ingelheim Pharmaceuticals, Inc. 2025 Label. FDA Label (PDF)Primary source for all dosing, adverse event Table 1, pharmacokinetic data (Cmax, t½, protein binding), and contraindications/warnings.
- Ipratropium Bromide Inhalation Solution 0.02% (500 mcg/2.5 mL). Full Prescribing Information. DailyMedSource for nebulizer solution dosing, pharmacokinetics after nebulization (~4% urinary excretion), and combination data with albuterol.
- ATROVENT Nasal Spray 0.03% and 0.06% (ipratropium bromide). Full Prescribing Information. FDA Label (PDF)Source for nasal spray indications (rhinorrhea), dosing, and pediatric safety data.
- Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of COPD, 2024 Report. goldcopd.orgPositions SAMA (ipratropium) and SABA as initial therapy for mild COPD, with LAMAs preferred for maintenance in persistent disease.
- Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention, 2024 Update. ginasthma.orgRecommends nebulized ipratropium + SABA in the first hour of moderate-to-severe asthma exacerbation management.
- National Asthma Education and Prevention Program (NAEPP). Expert Panel Report 4 (EPR-4), 2020. doi:10.1016/j.jaci.2020.10.003US guideline recommending ipratropium + SABA for severe acute asthma exacerbations; documents doses for adults and children.
- Rodrigo GJ, Rodrigo C. The role of anticholinergics in acute asthma treatment: an evidence-based evaluation. Chest. 2002;121(6):1977–1987. doi:10.1378/chest.121.6.1977Meta-analysis demonstrating that adding ipratropium to SABA in acute severe asthma reduces hospitalization rates.
- Plotnick LH, Ducharme FM. Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. Cochrane Database Syst Rev. 2000;(4):CD000060. doi:10.1002/14651858.CD000060Cochrane review supporting ipratropium + SABA in pediatric acute asthma to reduce hospitalization.
- Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: the Lung Health Study. JAMA. 1994;272(19):1497–1505. doi:10.1001/jama.1994.03520190043033Landmark Lung Health Study; ipratropium improved FEV1 short-term but did not significantly alter long-term decline in COPD.
- Gross NJ. Ipratropium bromide. N Engl J Med. 1988;319(8):486–494. doi:10.1056/NEJM198808253190806Comprehensive review of ipratropium pharmacology, clinical efficacy in COPD, and comparison with beta-agonists.
- Barnes PJ. The role of anticholinergics in chronic obstructive pulmonary disease. Am J Med. 2004;117 Suppl 12A:24S–32S. doi:10.1016/j.amjmed.2004.10.018Reviews muscarinic receptor subtypes in the lung and the rationale for anticholinergic bronchodilation in COPD vs asthma.
- Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease (UPLIFT). N Engl J Med. 2008;359(15):1543–1554. doi:10.1056/NEJMoa0805800UPLIFT trial establishing tiotropium (LAMA) superiority over ipratropium for COPD maintenance, contextualizing ipratropium in modern COPD management.